Crystalline forms of psilacetin
Crystalline forms of 4-acetoxy-N,N-dimethyltryptamine (psilacetin), compositions containing that crystalline form, and their methods of use are disclosed. The crystalline forms of 4-acetoxy-N,N-dimethyltryptamine (psilacetin) according to the disclosure include crystalline 4-acetoxy-N,N-dimethyltryptammonium hydrofumarate, the fumarate salt of psilacetin, and/or crystalline bis(4-acetoxy-N,N-dimethyltryptammonium) fumarate, and pharmaceutical compositions containing a crystalline form of psilacetin.
1. Crystalline 4-acetoxy-N,N-dimethyltryptammonium hydrofumarate.
2. Crystalline 4-acetoxy-N,N-dimethyltryptammonium hydrofumarate according to claim 1 characterized by:
a monoclinic, P2 1 Ic crystal system space group at a temperature of about 296 K, unit cell dimensions a=13.023 (1) Å, b=7.4823 (6) Å, c=19.102 (2) Å, α=90°, β=(3 103.251(3)°, and γ=90° at a temperature of about 296 K;
a x-ray powder diffraction pattern substantially similar to FIG. 4 ; or
an x-ray powder diffraction pattern characterized by peaks at 7.0, 13.0 and 21.8° 2θ±0.2° 2θ.
3. A composition comprising crystalline 4-acetoxy-N,N-dimethyltryptammonium hydrofumarate according to claim 1 and an excipient.
4. A composition comprising as crystalline 4-acetoxy-N,N-dimethyltryptammonium hydrofumarate and a second component selected from (a) a purified psilocybin derivative, (b) one or two purified cannabinoids and (c) a purified terpene.
5. A method of treating or reducing the incidence of a psychological disorder comprising the step of:
administering to a subject in need thereof a therapeutically effective amount of crystalline 4-acetoxy-N,N-dimethyltryptammonium hydrofumarate according to claim 1 .
6. A method of treating or reducing the incidence of a psychological disorder comprising the step of:
administering to a subject in need thereof a therapeutically effective amount of crystalline 4-acetoxy-N,N-dimethyltrybtammonium hydrofumarate according to claim 2 .
7. A method of treating or reducing the incidence of a psychological disorder comprising the step of:
administering to a subject in need thereof a composition according to claim 3 .
8. A method of treating or reducing the incidence of inflammation and/or pain comprising the step of:
administering to a subject in need thereof a therapeutically effective amount of crystalline 4-acetoxy-N,N-dimethyltryptammonium hydrofumarate according to claim 1 .
9. A method of treating or reducing the incidence of inflammation and/or pain comprising the step of:
administering to a subject in need thereof a therapeutically effective amount of crystalline 4-acetoxy-N,N-dimethyltryptammonium hydrofumarate according to claim 2 .
10. A method of treating or reducing the incidence of inflammation and/or pain comprising the step of:
administering to a subject in need thereof a composition according to claim 3 .